The drive to develop new prophylactic vaccines has resulted from the increase in impact of emerging diseases, bioterrorism and resistance to existing antimicrobials, as well as the apparent increased virulence of some viruses, such as influenza. Charles River is working with companies that develop vaccines by providing in vivo challenge studies, in addition to a large portfolio of vaccine testing options.
Studies involve the deliberate infection of a healthy host, allowing for a greater understanding of the infecting pathogen and the potency/efficacy of a product. Many ethical and safety considerations need to be addressed for such studies, and assessment is dependent on the pathogen, route of administration and host species.
For those companies developing influenza vaccines, Charles River has added the capability to conduct short- and long-term influenza studies in ferrets and rodents under BSL-2 containment. Hemagglutination assay (HA), hemagglutination inhibition assay (HAI) and EID50 (embryo infectious dose) testing can also be conducted on samples generated during influenza studies.
View a video of our vaccine challenge facility »